LY M003
Alternative Names: LY-M003Latest Information Update: 25 Oct 2024
At a glance
- Originator Lingyi Biotech
- Class Gene therapies
- Mechanism of Action Copper-transporting ATPase replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Hepatolenticular degeneration
Most Recent Events
- 24 Sep 2024 Phase-0 for Hepatolenticular degeneration in China (IV) (NCT06650319)
- 20 Dec 2023 Early research in Metabolic disorders in China (Parenteral), prior to December 2023 (Lingyi Biotech pipeline, December 2023)